chufangao/CTO huggingface dataset:
Clinical trial NCT03398148: A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Participants With Moderately to Severely Active Ulcerative Colitis
Official title: A Multicenter, Randomized, Double-Blind, Placebo Controlled Induction Study to Evaluate the Efficacy and Safety of Risankizumab in Subjects With Moderately to Severely Active Ulcerative Colitis
Sponsor: AbbVie (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: COMPLETED 
Enrollment: 1558.0 (ACTUAL)
Number of arms: 15.0
Start date: 2018-03-07
Primary completion date: 2022-11-09
Completion date: 2023-05-11
Plan to share individual participant data: YES
IPD sharing description: AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information (e.g., protocols, analyses plans, clinical study reports), as long as the trials are not part of an ongoing or planned regulatory submission. This includes requests for clinical trial data for unlicensed products and indications.
IPD time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/
IPD access criteria: Access to this clinical trial data can be requested by any qualified researchers who engage in rigorous independent scientific research, and will be provided following review and approval of a research proposal and statistical analysis plan and execution of a data sharing statement. Data requests can be submitted at any time after approval in the US and/or EU and a primary manuscript is accepted for publication. For more information on the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Clinical trial NCT03498716: A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
Official title: A Phase III, Multicenter, Randomized, Open-Label Study Comparing Atezolizumab (Anti PD-L1 Antibody) in Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone in Patients With Operable Triple Negative Breast Cancer
Acronym: IMpassion030
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The study was terminated by the sponsor following interim analysis as the primary endpoint of iDFS crossed the pre-specified futility boundary of hazard ratio \> 1 in the Intent-to-Treat (ITT) population.
Enrollment: 2199.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-08-02
Primary completion date: 2023-08-14
Completion date: 2023-08-14
Baseline population: Intent-to-Treat (ITT) population included all randomized participants, whether or not the assigned study treatment was received.
Clinical trial NCT02783404: An Oral Amoxicillin-Clavulanate Regimen to Prevent Bacteremia Following Dental Procedures
Official title: An Oral Amoxicillin-Clavulanate Regimen to Prevent Bacteremia Following
Sponsor: University of Santiago de Compostela (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: TERMINATED 
Why stopped: Significant results (no control neither amoxicillin new arms needed)
Enrollment: 40.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-02-27
Primary completion date: 2021-12-01
Completion date: 2022-05-17
Plan to share individual participant data: YES
IPD sharing description: IPD will be available on request
IPD time frame: By the end of the study (for 1 year)
IPD access criteria: On request
Clinical trial NCT02924376: Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)
Official title: A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Including FGFR2 Translocations Who Failed Previous Therapy - (FIGHT-202)
Sponsor: Incyte Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 147.0 (ACTUAL)
Number of arms: 3.0
Start date: 2017-01-16
Primary completion date: 2022-02-01
Completion date: 2022-02-01
Plan to share individual participant data: YES
IPD sharing description: Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.~The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency
IPD time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.
IPD access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.
Clinical trial NCT03337724: A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Official title: A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Patients With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer
Acronym: IPATunity130
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 579.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-01-06
Primary completion date: 2023-01-04
Completion date: 2023-01-04
Baseline population: Intention-to-treat (ITT) Population included all randomized participants in Cohorts A and B regardless of whether the participants received the assigned treatment. For Cohort C, the ITT population consisted of all enrolled participants in Cohort C.
Clinical trial NCT02859064: Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
Official title: A Phase II Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres (SIR-Spheres®)
Sponsor: SCRI Development Innovations, LLC (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Closed due to slow accrual
Enrollment: 6.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-07-28
Primary completion date: 2022-05-27
Completion date: 2022-06-10
Baseline population: All patients who received at least one dose of treatment of lanreotide and Y-90 microspheres.
Plan to share individual participant data: NO
Clinical trial NCT02120157: Myeloablative Haploidentical BMT With Post-transplant Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Official title: Pediatric Blood & Marrow Transplant Consortium (PBMTC) Phase II Myeloablative Haploidentical BMT With Post-transplantation Cyclophosphamide for Pediatric Patients With Hematologic Malignancies
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 35.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-07-02
Primary completion date: 2018-06-15
Completion date: 2020-10-01
Plan to share individual participant data: NO
Clinical trial NCT02452268: A Phase I/Ib Study of NIZ985 in Combination With PDR001 in Adults With Metastatic Cancers
Official title: A Phase 1 Study of Subcutaneous Recombinant Human NIZ985 ((hetIL-15) (IL15/sIL-15Ra)) Alone and in Combination With PDR001 in Adults With Metastatic Cancers
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: business decision
Enrollment: 83.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-05-08
Primary completion date: 2022-03-07
Completion date: 2022-03-07
Plan to share individual participant data: NO
Clinical trial NCT04441099: NBE-002 in Patients With Advanced Solid Tumors
Official title: A First-in-Human, Phase 1/2 Study of NBE-002, an Anti-ROR1 Antibody Drug Conjugate, in Patients With Advanced Solid Tumors
Sponsor: NBE-Therapeutics AG (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: TERMINATED 
Why stopped: End of Program
Enrollment: 12.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-06-19
Primary completion date: 2023-08-14
Completion date: 2023-08-14
Plan to share individual participant data: NO
Clinical trial NCT02638519: HP Xenon-129 fMRI of Healthy Volunteers and Participants With Alzheimer's Disease
Official title: Hyperpolarized Xenon-129 Functional Magnetic Resonance Imaging of Healthy Volunteers and Participants With Alzheimer's Disease
Sponsor: Thunder Bay Regional Health Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Unable to reach the target enrollment of 40 participants with Alzheimer's disease.
Enrollment: 51.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-06-27
Primary completion date: 2022-04-19
Completion date: 2022-04-19
Clinical trial NCT04374474: Anosmia Rehabilitation in Patients Post Coronavirus Disease (COVID 19)
Official title: Olfactory Retraining Therapy and Budesonide Nasal Rinse for Anosmia Treatment in Patients Post-CoVID 19. A Randomized Controlled Trial
Sponsor: Lawson Health Research Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: WITHDRAWN 
Why stopped: Study withdrawn before any enrollment (site's research goals adjustments).
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2021-01-10
Primary completion date: 2021-12-10
Completion date: 2022-03-10
Clinical trial NCT03499119: AMG 334 20160172 Pediatric Migraine PK Study.
Official title: A Phase I, Randomized, Open-label, Multiple-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of AMG 334 in Children and Adolescents With Migraine
Sponsor: Amgen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 53.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-05-04
Primary completion date: 2021-11-23
Completion date: 2021-11-23
Baseline population: The full analysis set included all randomized participants.
Plan to share individual participant data: YES
IPD sharing description: De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.
IPD time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
IPD access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
Clinical trial NCT04294654: Vortioxetine in Patients With Depression and Early Dementia
Official title: Interventional, Open-label Study of Flexible Doses of Vortioxetine on Depressive Symptoms in Patients With Major Depressive Disorder and Early Dementia
Acronym: MEMORY
Sponsor: H. Lundbeck A/S (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 82.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-02-28
Primary completion date: 2022-07-06
Completion date: 2022-07-20
Plan to share individual participant data: UNDECIDED
Clinical trial NCT04113889: Effects of Triple Drug Cocktail Therapy on Metabolic, Endocrine Alterations and Perceived Stress in Patients With Poly Cystic Ovary Syndrome
Official title: Effects of Triple Drug Cocktail Therapy on Metabolic, Endocrine Alterations and Perceived Stress Response in Patients With PCOS: A Double Blind Randomized Clinical Trial
Acronym: PCOS
Sponsor: Khyber Medical University Peshawar (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 147.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-10-15
Primary completion date: 2020-01-30
Completion date: 2020-01-30
Plan to share individual participant data: NO
Clinical trial NCT03451006: Effect of Metformin on Frailty in 12 Subjects
Official title: (MATE) Metformin and Aging Trial in the Elderly: A Pilot and Feasibility Study
Sponsor: Mayo Clinic (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: difficult recruitment and not achieved
Enrollment: 7.0 (ACTUAL)
Number of arms: 2.0
Start date: 2018-05-24
Primary completion date: 2021-12-16
Completion date: 2021-12-16
Limitations and caveats: Study was terminated due to recruitment being difficult and not achieved.
Plan to share individual participant data: NO
IPD sharing description: No plan to do that
Clinical trial NCT02400814: MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung Cancer
Official title: Pilot Study of MPDL3280A Plus Stereotactic Ablative Radiotherapy (SAR) in Stage IV Non-small Cell Lung Cancer
Sponsor: University of California, Davis (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Enrollment halted due to slow accrual.
Enrollment: 27.0 (ACTUAL)
Number of arms: 3.0
Start date: 2015-12-03
Primary completion date: 2021-09-29
Completion date: 2021-09-29
Clinical trial NCT03487848: Evaluation of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children With Chronic Hepatitis C (CHC) Infection
Official title: Open-Label, Single-Arm Trial to Evaluate the Pharmacokinetics, Safety and Efficacy of Daclatasvir (DCV) in Combination With Sofosbuvir (SOF) in Children From 3 to Less Than 18 Years of Age With GT-1 to -6 Chronic Hepatitis C (CHC) Infection
Sponsor: Bristol-Myers Squibb (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Business objectives have changed
Enrollment: 5.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-06-25
Primary completion date: 2018-10-18
Completion date: 2020-09-17
Limitations and caveats: This study was terminated early by sponsor for reasons unrelated to safety.
Clinical trial NCT02608229: BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Official title: Phase Ib Study of BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer
Sponsor: Washington University School of Medicine (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Adverse events
Enrollment: 18.0 (ACTUAL)
Number of arms: 2.0
Start date: 2016-06-06
Primary completion date: 2019-03-27
Completion date: 2020-05-21
Plan to share individual participant data: NO
Clinical trial NCT03342937: KeyLargo: Pembrolizumab + Oxaliplatin + Capecitabine in Gastric Cancer
Official title: A Single Arm, Phase II Study of Pembrolizumab, Oxaliplatin, and Capecitabine in the First Line Treatment of Patients With Gastro-esophageal Cancer.
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 36.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-01-11
Primary completion date: 2023-02-06
Completion date: 2023-02-06
Baseline population: The safety run-in was intended to identify dose-limiting toxicity. No DLTs were observed in the safety run-in and the drug dose levels were not changed in the expansion cohort, therefore; results were for safety validation and expansion were combined.
Clinical trial NCT04327934: Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome
Official title: Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome
Sponsor: Yale University (OTHER)
Study type: INTERVENTIONAL
Phase: EARLY_PHASE1
Status: TERMINATED 
Why stopped: Unble to complete all arms of the planned study due to Covid stoppage and difficulty with recruiting and getting enrolled participants to return post Covid.
Enrollment: 28.0 (ACTUAL)
Number of arms: 2.0
Start date: 2017-12-01
Primary completion date: 2022-06-30
Completion date: 2022-06-30
Baseline population: Baseline characteristics are presented for people that completed the study- which is defined as those that were allocated, began and completed the study.
Limitations and caveats: Our primary limitation was stoppage due to Covid (our laboratory was forced to close). We also had a very challenging time recruiting subjects when we reopened after the three-month closure under new rules. Subjects who had been enrolled did not return, and new subjects were difficult to recruit. Thus, we were not able to complete all arms of the planned study. We were able to answer our primary questions regarding autonomic function in women with PCOS.
Clinical trial NCT02007512: Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer
Official title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY OF EFFICACY AND SAFETY OF ENZALUTAMIDE IN COMBINATION WITH EXEMESTANE IN PATIENTS WITH ADVANCED BREAST CANCER THAT IS ESTROGEN OR PROGESTERONE RECEPTOR-POSITIVE AND HER2-NORMAL
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 247.0 (ACTUAL)
Number of arms: 2.0
Start date: 2013-12-16
Primary completion date: 2016-09-23
Completion date: 2024-07-19
Baseline population: Intent-to-treat (ITT) population included all the participants randomly assigned to double-blind study treatment.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT02264236: Vaccination of Advanced-Stage Lung Cancer Patients
Official title: Vaccination of Advanced-Stage Lung Cancer Patients A Phase I/II Study of a Carbohydrate Mimotope Based Vaccine With MONTANIDETM ISA 51 VG ST Adjuvant
Sponsor: University of Arkansas (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: Inability to enroll subjects under current iteration of the protocol
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2015-10-31
Primary completion date: 2021-06-30
Completion date: 2021-06-30
Clinical trial NCT03948464: Slow-Release Oral Morphine for the Treatment of Opioid Use Disorder
Official title: Repurposing Slow-Release Oral Morphine as a New Oral Alternative for the Treatment of Opioid Use Disorder
Acronym: pRESTO
Sponsor: BC Centre on Substance Use (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Study unable to proceed per protocol due to COVID-19 precautions
Enrollment: 27.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-12-06
Primary completion date: 2020-06-01
Completion date: 2020-06-01
Plan to share individual participant data: NO
Clinical trial NCT02555293: Administration of Rifaximin to Improve Liver Regeneration and Outcome Following Major Liver Resection
Official title: Administration of Rifaximin to Improve Liver Regeneration and Outcome Following Major Liver Resection
Acronym: ARROW
Sponsor: RWTH Aachen University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Prematurely terminated due to organisational reasons
Enrollment: 96.0 (ESTIMATED)
Number of arms: 2.0
Start date: 2016-02-29
Primary completion date: 2020-11-20
Completion date: 2020-11-20
Clinical trial NCT05036135: A Study of AV-101 (Dry Powder Inhaled Imatinib) in Patients With Pulmonary Arterial Hypertension (PAH)
Official title: IMPAHCT: A Phase 2b/3, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Ranging and Confirmatory Study to Evaluate the Safety and Efficacy of AV-101 in Patients With Pulmonary Arterial Hypertension (PAH)
Acronym: IMPAHCT
Sponsor: Aerovate Therapeutics (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: TERMINATED 
Why stopped: The IMPAHCT study demonstrated that while inhaled imatinib was well tolerated, it did not prove to be efficacious at any of the doses of AV-101 evaluated in the study.
Enrollment: 202.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-12-02
Primary completion date: 2024-08-09
Completion date: 2024-08-09
Plan to share individual participant data: NO
Clinical trial NCT02340221: A Study of Taselisib + Fulvestrant Versus Placebo + Fulvestrant in Participants With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy
Official title: A Phase III, Double-Blind, Placebo-Controlled, Randomized Study of Taselisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Postmenopausal Women With Estrogen Receptor-Positive and HER2-Negative Locally Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy
Acronym: SANDPIPER
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The Sponsor discontinued the manufacturing and development of taselisib due to modest clinical benefit and limited tolerability.
Enrollment: 631.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-04-09
Primary completion date: 2021-06-29
Completion date: 2021-06-29
Baseline population: The intent-to-treat (ITT) population included all randomized participants regardless of whether they received any amount of study treatment.
Clinical trial NCT05327855: Efficacy and Safety of OPL-0301 Compared to Placebo in Adults With Post-Myocardial Infarction (MI)
Official title: A Phase 2, Randomized, Double-blind, Placebo-controlled, Multiple-arm, Parallel-group, Adaptive Study to Investigate the Efficacy and Safety of OPL-0301 in Patients With Post-myocardial Infarction Left Ventricular Dysfunction (RESTORE)
Acronym: RESTORE
Sponsor: Valo Health, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Withdrawn based on business decision, no participants enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2022-09-30
Primary completion date: 2024-08-31
Completion date: 2024-11-30